Immunocore Holdings (IMCR) Current Deferred Revenue (2019 - 2026)

Immunocore Holdings (IMCR) has reported Current Deferred Revenue for 7 consecutive years, with $572000.0 the latest figure, recorded in Q1 2026.

• Quarterly Current Deferred Revenue changed N/A year-over-year to $572000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $572000.0 (changed N/A YoY) and the FY2025 annual result came in at $583000.0, changed N/A from the prior year.
• Current Deferred Revenue slipped to $572000.0 in Q1 2026 per IMCR's latest filing, from $583000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for IMCR reached as high as $12.6 million in Q3 2022 and fell as low as $572000.0 in Q1 2026.
• A 4-year average of $3.8 million and a median of $594000.0 in 2025 frame the typical range for Current Deferred Revenue.
• The largest YoY upside for Current Deferred Revenue was 77.2% in 2022 against a maximum downside of 77.2% in 2022.
• Year by year, Current Deferred Revenue stood at $7.5 million in 2022, then slumped by 46.66% to $4.0 million in 2023, then plunged by 85.46% to $583000.0 in 2025, then fell by 1.89% to $572000.0 in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $572000.0, $583000.0, and $582000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.